Kirchheimer J C, Remold H G
Department of Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA 02115.
Blood. 1989 Sep;74(4):1396-402.
We compared urokinase-type plasminogen activator (u-PA) in fluid phase and u-PA bound with its receptor on human blood monocytes with respect to proteolytic activity and susceptibility to inactivation by the plasminogen activator inhibitors PAI-1 and PAI-2. Receptor-bound u-PA is catalytically twice as efficient as fluid-phase u-PA. Fluid-phase u-PA is susceptible to rapid inhibition by PAI-1 and PAI-2 at an estimated PAI:u-PA molar ratio of 2:1. In contrast, u-PA bound to endogenously occupied receptors is inhibited by PAI-2 only at PAI:u-PA molar ratios of 20:1, but is not inhibited by PAI-1, u-PA/PAI-1 and u-PA/PAI-2 complexes bind to the receptor with a tenfold lower affinity than u-PA itself. Thus, competition of u-PA/PAI complexes with fluid-phase u-PA for binding to the receptor is unlikely to affect the overall plasminogen activator activity of the monocyte. These findings demonstrate that the activity of receptor-bound u-PA can be modulated by PAI-2, but not by PAI-1, to adjust the cell's proteolytic activity to different local situations.
我们比较了液相中的尿激酶型纤溶酶原激活剂(u-PA)以及与人血单核细胞上其受体结合的u-PA在蛋白水解活性和对纤溶酶原激活剂抑制剂PAI-1和PAI-2失活的敏感性方面的差异。与受体结合的u-PA在催化效率上是液相u-PA的两倍。液相u-PA在估计的PAI:u-PA摩尔比为2:1时易被PAI-1和PAI-2快速抑制。相比之下,与内源性占据的受体结合的u-PA仅在PAI:u-PA摩尔比为20:1时被PAI-2抑制,但不被PAI-1抑制,u-PA/PAI-1和u-PA/PAI-2复合物与受体结合的亲和力比u-PA本身低十倍。因此,u-PA/PAI复合物与液相u-PA竞争结合受体不太可能影响单核细胞的整体纤溶酶原激活剂活性。这些发现表明,与受体结合的u-PA的活性可被PAI-2而非PAI-1调节,从而使细胞的蛋白水解活性适应不同的局部情况。